Key result
Finerenone lowers daytime systolic BP by ~7 mm Hg in patients with primary aldosteronism.
Why the study?
Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist, but robust evidence regarding its efficacy and safety in primary aldosteronism is scarce.
Does finerenone reduce daytime systolic blood pressure in adults with primary aldosteronism?
Does finerenone reduce daytime systolic blood pressure in adults with primary aldosteronism?
Finerenone effectively reduces blood pressure and corrects hypokalemia in patients with primary aldosteronism, suggesting it may be a viable alternative to spironolactone.
Finerenone was associated with BP reductions in primary aldosteronism; leaves open its role versus spironolactone pending RCTs.
BACKGROUND: Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist. However, robust evidence about its efficacy and safety in primary aldosteronism is scarce. METHODS: In this prospective, multicenter, single-arm, and exploratory trial, we enrolled adults (aged ≤75 years) with primary aldosteronism, an office blood pressure (BP) ranging from 140 to 180/90 to 120 mm Hg, and an estimated glomerular filtration rate ≥60 mL/min per 1.73 m². Eligible patients received finerenone (20–40 mg/d) treatment for 12 weeks. The primary outcome was the change in daytime systolic BP at 12 weeks. RESULTS: Fifty-seven patients were ultimately treated. Per-protocol analysis revealed that finerenone treatment significantly reduced mean daytime systolic BP (−6.69±1.60 mm Hg; P <0.001) and diastolic BP (−4.55±1.06 mm Hg; P <0.001) according to ambulatory monitoring. Mean office BP decreased even more substantially (systolic BP, −15.58±1.69 mm Hg; diastolic BP, −8.61±1.02 mm Hg; both P <0.001). The mean increase in serum potassium concentration was 0.39±0.05 mmol/L, and 94.5% of patients exhibited a normal concentration after 12 weeks of treatment (versus baseline 61.8%; P <0.001). Plasma renin activity increased, and 32.7% of patients exhibited a plasma renin activity concentration ≥1 ng/mL per h. According to the Primary Aldosteronism Medical Treatment Outcome criteria, 29.1% and 20.0% of patients achieved complete biochemical and clinical responses, respectively. Treatment was well tolerated. CONCLUSIONS: This study demonstrated the efficacy and safety of finerenone in the treatment of primary aldosteronism, supporting its use as a potential alternative therapy for the condition. Nevertheless, further prospective and head-to-head randomized controlled trials are essential to establish finerenone as a viable substitute for spironolactone. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06381323.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question. Finerenone reduced mean daytime systolic BP by 6.69 mm Hg and diastolic BP by 4.55 mm Hg in patients with primary aldosteronism after 12 weeks of treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: